Key result
Study outlines validation protocol for HFA-ICOS score in predicting anthracycline-induced cardiotoxicity.
Why the study?
The HFA-ICOS risk score for predicting baseline cardiovascular risk in patients starting anthracycline chemotherapy has limited validation, especially in Asian populations.
Does the HFA-ICOS risk score predict anthracycline-induced cardiotoxicity in a Japanese cancer patient population?
Cohort
Does the HFA-ICOS risk score predict anthracycline-induced cardiotoxicity in a Japanese cancer patient population?
Answers are grounded in this paper and cite their sources.
This study aims to externally validate the HFA-ICOS risk score for predicting anthracycline-induced cardiotoxicity in an Asian population.
A nthracyclines are widely used chemothera- peutic agents, but their effectiveness can be limited by cancer therapy-related cardiac dysfunction (CTRCD).Recently, a predictive risk score to estimate baseline cardiovascular risk in patients starting cardiotoxic therapies, including anthracyclines, was developed by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS) 1 and is recommended in the 2022 European Society of Cardiology guidelines on cardio-oncology. 2 The score incorporates clinical factors such as patient-related cardiovascular risk factors, prior cardiovascular disease, and cancer therapy-related variables to estimate baseline cardiotoxicity risk. 2 However, this model has limited validation, particularly in Asian populations.Therefore, we performed an external validation of the HFA-ICOS risk score using the AIC Registry in Japan.3,4 This study followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis statement for prediction model validation.5 The study was based on data from patients with cancer who were receiving anthracycline chemotherapy and were prospectively enrolled in the AIC Registry between July 2016 and October 2021.3,4 Patients with baseline left ventricular ejection fractions (LVEF) of <50%, moderate or greater valvular disease, congenital heart disease, or cardiomyopathy were excluded.Clinical and echocardiographic data were prospectively collected before starting anthracyclines and during follow-up.The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of Tsukuba Hospital (H28-06).Written informed consent was obtained from all patients.The primary endpoint was CTRCD during the 2-year follow-up period, defined as a $10% reduction in LVEF to <55%.6 The follow-up period was based on the AIC Registry design, 4 a time frame considered clinically relevant for cardiotoxicity.The HFA-ICOS score was calculated using baseline variables, and patients were stratified into low-, moderate-, and high-risk groups according to predefined thresholds. 1 There were no missing data required to calculate the score.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) conducted a cohort in Cancer therapy-related cardiac dysfunction (CTRCD). HFA-ICOS risk score was evaluated on CTRCD during the 2-year follow-up period (defined as a ≥10% reduction in LVEF to <55%).
Synapse has enriched 10 related papers. Consider them for comparative context: